Key Insights

Highlights

Success Rate

89% trial completion (above average)

Published Results

61 trials with published results (32%)

Research Maturity

142 completed trials (75% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

9.5%

18 terminated out of 190 trials

Success Rate

88.8%

+2.2% vs benchmark

Late-Stage Pipeline

38%

72 trials in Phase 3/4

Results Transparency

43%

61 of 142 completed with results

Key Signals

61 with results89% success18 terminated

Data Visualizations

Phase Distribution

154Total
Not Applicable (14)
Early P 1 (2)
P 1 (23)
P 2 (43)
P 3 (30)
P 4 (42)

Trial Status

Completed142
Terminated18
Withdrawn11
Unknown8
Recruiting7
Active Not Recruiting2

Trial Success Rate

88.8%

Benchmark: 86.5%

Based on 142 completed trials

Clinical Trials (190)

Showing 20 of 20 trials
NCT01511588Completed

Hormonal Regulation of Puberty and Fertility

NCT01500447Recruiting

Inherited Reproductive Disorders

NCT03887936Phase 4Completed

Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism

NCT07546435Recruiting

Male Experiences With Intra Cytoplasmic Sperm Injection (ICSI) and Reduced Sperm Quality

NCT07535905Phase 2Not Yet RecruitingPrimary

Clinical Trial to Observe the Effects of Tamoxifen on Testosterone Recovery in Medically Castrated Prostate Cancer Patients

NCT07097259Phase 1CompletedPrimary

A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male Participants

NCT04731376Phase 1Active Not RecruitingPrimary

Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone

NCT06280807RecruitingPrimary

Observation of Environment and Reproductive-Endocrine Effects

NCT06191575SuspendedPrimary

7 Tesla MRI Neuroimaging in Testicular Cancer Patients With Hypogonadism and on Androgen Replacement Therapy

NCT06385509Phase 4Active Not RecruitingPrimary

A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months

NCT06455969Phase 4Recruiting

Adaptions and Resiliency to Multi-Stressor OpeRations

NCT06247267RecruitingPrimary

The Effect of Sex Steroid Replacement Therapy in the Hypogonadism and Transgender Active-Duty Population

NCT04460872Phase 2Recruiting

Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury

NCT04833426Phase 3Recruiting

Impact of Peri-operative tEstosterone Levels on oNcological and Functional Outcomes in RadiCal prostatEctomy

NCT04456296Phase 4CompletedPrimary

A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism

NCT02514629Phase 3CompletedPrimary

Testosterone, Metformin, or Both, for Hypogonadism in Obese Males

NCT02758431Not ApplicableCompletedPrimary

Cardiovascular Outcomes of Low Testosterone

NCT02956447Phase 2Completed

Administration of Kisspeptin in Patients With Hyperprolactinemia

NCT01709331Phase 3CompletedPrimary

A Study of the Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adult Men With Hypogonadotropic Hypogonadism (HH) (P07937)

NCT05752591Completed

Hypothalamic-pituitary Dysfunction in Diabetes

Scroll to load more

Research Network

Activity Timeline